Lutetium Lu 177 Vipivotide Tetraxetan

Lutetium Lu 177 Vipivotide Tetraxetan · Targeted Radiopharmaceutical / Radioligand Therapy

Back to Cancer Drug Encyclopedia Find Recruiting Trials with this Drug →

Indications & Uses

PSMA-positive Metastatic Castration-Resistant Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), and Pheochromocytoma.

Contraindications

Hypersensitivity to active ingredient or any formulation excipients.

Side Effects & Warnings

Myelosuppression, radiation exposure, dry mouth/xerostomia, renal toxicity, nausea, fatigue.

Drug & Dietary Interactions

Caution with strong CYP3A inhibitors or inducers; review concurrent medications.

For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.

Patient & Caregiver Support

Ask About This Medication

Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.